Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sarah J. Hepworth is active.

Publication


Featured researches published by Sarah J. Hepworth.


Nature Genetics | 2009

Genome-wide association study identifies five susceptibility loci for glioma.

Sanjay Shete; Fay J. Hosking; Lindsay B. Robertson; Sara E. Dobbins; Marc Sanson; Beatrice Malmer; Matthias Simon; Yannick Marie; Blandine Boisselier; Jean Yves Delattre; Khê Hoang-Xuan; Soufiane El Hallani; Ahmed Idbaih; Diana Zelenika; Ulrika Andersson; Roger Henriksson; A. Tommy Bergenheim; Maria Feychting; Stefan Lönn; Anders Ahlbom; Johannes Schramm; Michael Linnebank; Kari Hemminki; Rajiv Kumar; Sarah J. Hepworth; Amy Price; Georgina Armstrong; Yanhong Liu; Xiangjun Gu; Robert Yu

To identify risk variants for glioma, we conducted a meta-analysis of two genome-wide association studies by genotyping 550K tagging SNPs in a total of 1,878 cases and 3,670 controls, with validation in three additional independent series totaling 2,545 cases and 2,953 controls. We identified five risk loci for glioma at 5p15.33 (rs2736100, TERT; P = 1.50 × 10−17), 8q24.21 (rs4295627, CCDC26; P = 2.34 × 10−18), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 × 10−15), 20q13.33 (rs6010620, RTEL1; P = 2.52 × 10−12) and 11q23.3 (rs498872, PHLDB1; P = 1.07 × 10−8). These data show that common low-penetrance susceptibility alleles contribute to the risk of developing glioma and provide insight into disease causation of this primary brain tumor.


European Journal of Epidemiology | 2007

The INTERPHONE study: design, epidemiological methods, and description of the study population

Elisabeth Cardis; Lesley Richardson; Isabelle Deltour; Bruce K. Armstrong; Maria Feychting; Christoffer Johansen; Monique Kilkenny; Patricia A. McKinney; Baruch Modan; Siegal Sadetzki; Joachim Schüz; Anthony J. Swerdlow; Martine Vrijheid; Anssi Auvinen; Gabriele Berg; Maria Blettner; Joseph D. Bowman; Julianne Brown; Angela Chetrit; Helle Collatz Christensen; Angus Cook; Sarah J. Hepworth; Graham G. Giles; Martine Hours; Ivano Iavarone; Avital Jarus-Hakak; Lars Klæboe; Daniel Krewski; Susanna Lagorio; Stefan Lönn

The very rapid worldwide increase in mobile phone use in the last decade has generated considerable interest in the possible health effects of exposure to radio frequency (RF) fields. A multinational case–control study, INTERPHONE, was set-up to investigate whether mobile phone use increases the risk of cancer and, more specifically, whether the RF fields emitted by mobile phones are carcinogenic. The study focused on tumours arising in the tissues most exposed to RF fields from mobile phones: glioma, meningioma, acoustic neurinoma and parotid gland tumours. In addition to a detailed history of mobile phone use, information was collected on a number of known and potential risk factors for these tumours. The study was conducted in 13 countries. Australia, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Sweden, and the UK using a common core protocol. This paper describes the study design and methods and the main characteristics of the study population. INTERPHONE is the largest case–control study to date investigating risks related to mobile phone use and to other potential risk factors for the tumours of interest and includes 2,765 glioma, 2,425 meningioma, 1,121 acoustic neurinoma, 109 malignant parotid gland tumour cases and 7,658 controls. Particular attention was paid to estimating the amount and direction of potential recall and participation biases and their impact on the study results.


British Journal of Cancer | 2005

Mobile phone use and risk of acoustic neuroma: results of the Interphone case–control study in five North European countries

Minouk J. Schoemaker; Anthony J. Swerdlow; Anders Ahlbom; Anssi Auvinen; Kg Blaasaas; Elisabeth Cardis; H. Collatz Christensen; Maria Feychting; Sarah J. Hepworth; Christoffer Johansen; Lars Klæboe; Stefan Lönn; Patricia A. McKinney; Kenneth Muir; Jani Raitanen; Tina Salminen; Jens Thomsen; Tore Tynes

There is public concern that use of mobile phones could increase the risk of brain tumours. If such an effect exists, acoustic neuroma would be of particular concern because of the proximity of the acoustic nerve to the handset. We conducted, to a shared protocol, six population-based case–control studies in four Nordic countries and the UK to assess the risk of acoustic neuroma in relation to mobile phone use. Data were collected by personal interview from 678 cases of acoustic neuroma and 3553 controls. The risk of acoustic neuroma in relation to regular mobile phone use in the pooled data set was not raised (odds ratio (OR)=0.9, 95% confidence interval (CI): 0.7–1.1). There was no association of risk with duration of use, lifetime cumulative hours of use or number of calls, for phone use overall or for analogue or digital phones separately. Risk of a tumour on the same side of the head as reported phone use was raised for use for 10 years or longer (OR=1.8, 95% CI: 1.1–3.1). The study suggests that there is no substantial risk of acoustic neuroma in the first decade after starting mobile phone use. However, an increase in risk after longer term use or after a longer lag period could not be ruled out.


BMJ | 2006

Mobile phone use and risk of glioma in adults: case-control study

Sarah J. Hepworth; Minouk J. Schoemaker; Kenneth Muir; Anthony J. Swerdlow; Martie van Tongeren; Patricia A. McKinney

Abstract Objective To investigate the risk of glioma in adults in relation to mobile phone use. Design Population based case-control study with collection of personal interview data. Setting Five areas of the United Kingdom. Participants 966 people aged 18 to 69 years diagnosed with a glioma from 1 December 2000 to 29 February 2004 and 1716 controls randomly selected from general practitioner lists. Main outcome measures Odds ratios for risk of glioma in relation to mobile phone use. Results The overall odds ratio for regular phone use was 0.94 (95% confidence interval 0.78 to 1.13). There was no relation for risk of glioma and time since first use, lifetime years of use, and cumulative number of calls and hours of use. A significant excess risk for reported phone use ipsilateral to the tumour (1.24, 1.02 to 1.52) was paralleled by a significant reduction in risk (0.75, 0.61 to 0.93) for contralateral use. Conclusions Use of a mobile phone, either in the short or medium term, is not associated with an increased risk of glioma. This is consistent with most but not all published studies. The complementary positive and negative risks associated with ipsilateral and contralateral use of the phone in relation to the side of the tumour might be due to recall bias.


Occupational and Environmental Medicine | 2006

Validation of short term recall of mobile phone use for the Interphone study

Martine Vrijheid; Elisabeth Cardis; Bruce K. Armstrong; Anssi Auvinen; Gabriele Berg; Kg Blaasaas; Julianne Brown; Matthew Carroll; Angela Chetrit; Helle Collatz Christensen; Isabelle Deltour; Maria Feychting; Graham G. Giles; Sarah J. Hepworth; Martine Hours; Ivano Iavarone; Christoffer Johansen; Lars Klæboe; Päivi Kurttio; Susanna Lagorio; Stefan Lönn; Patricia A. McKinney; Lucile Montestrucq; Roger Parslow; Lesley Richardson; Siegal Sadetzki; Tiina Salminen; Joachim Schüz; Tore Tynes; Alistair Woodward

Aim: To validate short term recall of mobile phone use within Interphone, an international collaborative case control study of tumours of the brain, acoustic nerve, and salivary glands related to mobile telephone use. Methods: Mobile phone use of 672 volunteers in 11 countries was recorded by operators or through the use of software modified phones, and compared to use recalled six months later using the Interphone study questionnaire. Agreement between recalled and actual phone use was analysed using both categorical and continuous measures of number and duration of phone calls. Results: Correlations between recalled and actual phone use were moderate to high (ranging from 0.5 to 0.8 across countries) and of the same order for number and duration of calls. The kappa statistic demonstrated fair to moderate agreement for both number and duration of calls (weighted kappa ranging from 0.20 to 0.60 across countries). On average, subjects underestimated the number of calls per month (geometric mean ratio of recalled to actual = 0.92, 95% CI 0.85 to 0.99), whereas duration of calls was overestimated (geometric mean ratio = 1.42, 95% CI 1.29 to 1.56). The ratio of recalled to actual use increased with level of use, showing underestimation in light users and overestimation in heavy users. There was substantial heterogeneity in this ratio between countries. Inter-individual variation was also large, and increased with level of use. Conclusions: Volunteer subjects recalled their recent phone use with moderate systematic error and substantial random error. This large random error can be expected to reduce the power of the Interphone study to detect an increase in risk of brain, acoustic nerve, and parotid gland tumours with increasing mobile phone use, if one exists.


Human Molecular Genetics | 2011

Chromosome 7p11.2 (EGFR) variation influences glioma risk

Marc Sanson; Fay J. Hosking; Sanjay Shete; Diana Zelenika; Sara E. Dobbins; Yussanne Ma; Victor Enciso-Mora; Ahmed Idbaih; Jean Yves Delattre; Khê Hoang-Xuan; Yannick Marie; Blandine Boisselier; Catherine Carpentier; Xiao Wei Wang; Anna Luisa Di Stefano; Marianne Labussière; Konstantinos Gousias; Johannes Schramm; Anne Boland; Doris Lechner; Ivo Gut; Georgina Armstrong; Yanhong Liu; Robert Yu; Ching Lau; Maria Chiara Di Bernardo; Lindsay B. Robertson; Kenneth Muir; Sarah J. Hepworth; Anthony J. Swerdlow

While gliomas are the most common primary brain tumors, their etiology is largely unknown. To identify novel risk loci for glioma, we conducted genome-wide association (GWA) analysis of two case-control series from France and Germany (2269 cases and 2500 controls). Pooling these data with previously reported UK and US GWA studies provided data on 4147 glioma cases and 7435 controls genotyped for 424 460 common tagging single-nucleotide polymorphisms. Using these data, we demonstrate two statistically independent associations between glioma and rs11979158 and rs2252586, at 7p11.2 which encompasses the EGFR gene (population-corrected statistics, P(c) = 7.72 × 10(-8) and 2.09 × 10(-8), respectively). Both associations were independent of tumor subtype, and were independent of EGFR amplification, p16INK4a deletion and IDH1 mutation status in tumors; compatible with driver effects of the variants on glioma development. These findings show that variation in 7p11.2 is a determinant of inherited glioma risk.


Cancer Epidemiology | 2011

Acoustic neuroma risk in relation to mobile telephone use: Results of the INTERPHONE international case-control study

Elisabeth Cardis; Isabelle Deltour; Martine Vrijheid; A. S Evrard; M Moissonnier; Bruce K. Armstrong; Julianne Brown; Graham G. Giles; Jack Siemiatycki; Louise Nadon; Marie-Elise Parent; Daniel Krewski; M. M McBride; Christoffer Johansen; Helle Collatz Christensen; Anssi Auvinen; Päivi Kurttio; Anna Lahkola; Tina Salminen; Martine Hours; Marlène Bernard; L. Montestruq; Joachim Schüz; Maria Blettner; Gabriele Berg-Beckhoff; Brigitte Schlehofer; Siegal Sadetzki; Angela Chetrit; Avital Jarus-Hakak; Susanna Lagorio

BACKGROUND The rapid increase in mobile telephone use has generated concern about possible health risks of radiofrequency electromagnetic fields from these devices. METHODS A case-control study of 1105 patients with newly diagnosed acoustic neuroma (vestibular schwannoma) and 2145 controls was conducted in 13 countries using a common protocol. Past mobile phone use was assessed by personal interview. In the primary analysis, exposure time was censored at one year before the reference date (date of diagnosis for cases and date of diagnosis of the matched case for controls); analyses censoring exposure at five years before the reference date were also done to allow for a possible longer latent period. RESULTS The odds ratio (OR) of acoustic neuroma with ever having been a regular mobile phone user was 0.85 (95% confidence interval 0.69-1.04). The OR for ≥10 years after first regular mobile phone use was 0.76 (0.52-1.11). There was no trend of increasing ORs with increasing cumulative call time or cumulative number of calls, with the lowest OR (0.48 (0.30-0.78)) observed in the 9th decile of cumulative call time. In the 10th decile (≥1640 h) of cumulative call time, the OR was 1.32 (0.88-1.97); there were, however, implausible values of reported use in those with ≥1640 h of accumulated mobile phone use. With censoring at 5 years before the reference date the OR for ≥10 years after first regular mobile phone use was 0.83 (0.58-1.19) and for ≥1640 h of cumulative call time it was 2.79 (1.51-5.16), but again with no trend in the lower nine deciles and with the lowest OR in the 9th decile. In general, ORs were not greater in subjects who reported usual phone use on the same side of the head as their tumour than in those who reported it on the opposite side, but it was greater in those in the 10th decile of cumulative hours of use. CONCLUSIONS There was no increase in risk of acoustic neuroma with ever regular use of a mobile phone or for users who began regular use 10 years or more before the reference date. Elevated odds ratios observed at the highest level of cumulative call time could be due to chance, reporting bias or a causal effect. As acoustic neuroma is usually a slowly growing tumour, the interval between introduction of mobile phones and occurrence of the tumour might have been too short to observe an effect, if there is one.


International Journal of Cancer | 2006

History of allergies and risk of glioma in adults

Minouk J. Schoemaker; Anthony J. Swerdlow; Sarah J. Hepworth; Patricia A. McKinney; Martie van Tongeren; Kenneth Muir

Epidemiological studies have consistently reported an inverse association between a history of allergic disease and risk of glioma. The reason for this association is unclear, and there is a lack of studies with the detail and size to explore the association in depth. We conducted a UK population‐based case‐control study with 965 glioma cases and 1,716 controls to investigate glioma risk in relation to allergic disease. Risk was reduced in subjects reporting a history of asthma (odds ratio (OR) = 0.71, 95% confidence interval (CI): 0.54–0.92), hay fever (OR = 0.73, 95% CI: 0.59–0.90), eczema (OR = 0.74, 95% CI: 0.56–0.97) and other allergies (OR = 0.65, 95% CI: 0.47–0.90). Risk was reduced for all the main histological groups. There was no significant trend of risk with age, at the onset of each condition, or the number of conditions reported. Risk reductions were strongest for asthma or hay fever with recent onset. Risk in asthmatic subjects was not related to frequency of use of antiasthmatic drugs, but was significantly reduced for use of antiallergenic medication among subjects with hay fever. The study showed an inverse association of glioma risk with allergic disease. Possible reasons for the association, as well as potential immunological aetiology, include confounding, bias and reverse causality.


Journal of the National Cancer Institute | 2008

Comprehensive Analysis of DNA Repair Gene Variants and Risk of Meningioma

Lara Bethke; Anne Murray; Emily L. Webb; Minouk J. Schoemaker; Kenneth Muir; Patricia A. McKinney; Sarah J. Hepworth; Polyxeni Dimitropoulou; Artitaya Lophatananon; Maria Feychting; Stefan Lönn; Anders Ahlbom; Beatrice Malmer; Roger Henriksson; Anssi Auvinen; Anne Kiuru; Tiina Salminen; Christoffer Johansen; Helle Collatz Christensen; Michael Kosteljanetz; Anthony J. Swerdlow; Richard S. Houlston

BACKGROUND Meningiomas account for up to 37% of all primary brain tumors. Genetic susceptibility to meningioma is well established, with the risk among relatives of meningioma patients being approximately threefold higher than that in the general population. A relationship between risk of meningioma and exposure to ionizing radiation is also well known and led us to examine whether variants in DNA repair genes contribute to disease susceptibility. METHODS We analyzed 1127 tagging single-nucleotide polymorphisms (SNPs) that were selected to capture most of the common variation in 136 DNA repair genes in five case-control series (631 case patients and 637 control subjects) from four countries in Europe. We also analyzed 388 putative functional SNPs in these genes for their association with meningioma. All statistical tests were two-sided. RESULTS The SNP rs4968451, which maps to intron 4 of the gene that encodes breast cancer susceptibility gene 1-interacting protein 1, was consistently associated with an increased risk of developing meningioma. Across the five studies, the association was highly statistically significant (trend odds ratio = 1.57, 95% confidence interval = 1.28 to 1.93; P(trend) = 8.95 x 10(-6); P = .009 after adjusting for multiple testing). CONCLUSIONS We have identified a novel association between rs4968451 and meningioma risk. Because approximately 28% of the European population are carriers of at-risk genotypes for rs4968451, the variant is likely to make a substantial contribution to the development of meningioma.


Occupational and Environmental Medicine | 2009

Determinants of mobile phone output power in a multinational study: implications for exposure assessment

Martine Vrijheid; Simon Mann; Paolo Vecchia; Joe Wiart; Masao Taki; L. Ardoino; Bruce K. Armstrong; Anssi Auvinen; D. Bedard; Gabriele Berg-Beckhoff; Julianne Brown; Angela Chetrit; H. Collatz-Christensen; E. Combalot; Angus Cook; Isabelle Deltour; Maria Feychting; Graham G. Giles; Sarah J. Hepworth; Martine Hours; Ivano Iavarone; Christoffer Johansen; Daniel Krewski; Päivi Kurttio; Susanna Lagorio; Stefan Lönn; Mary L. McBride; L. Montestrucq; Roger Parslow; Siegal Sadetzki

Objectives: The output power of a mobile phone is directly related to its radiofrequency (RF) electromagnetic field strength, and may theoretically vary substantially in different networks and phone use circumstances due to power control technologies. To improve indices of RF exposure for epidemiological studies, we assessed determinants of mobile phone output power in a multinational study. Methods: More than 500 volunteers in 12 countries used Global System for Mobile communications software-modified phones (GSM SMPs) for approximately 1 month each. The SMPs recorded date, time, and duration of each call, and the frequency band and output power at fixed sampling intervals throughout each call. Questionnaires provided information on the typical circumstances of an individual’s phone use. Linear regression models were used to analyse the influence of possible explanatory variables on the average output power and the percentage call time at maximum power for each call. Results: Measurements of over 60 000 phone calls showed that the average output power was approximately 50% of the maximum, and that output power varied by a factor of up to 2 to 3 between study centres and network operators. Maximum power was used during a considerable proportion of call time (39% on average). Output power decreased with increasing call duration, but showed little variation in relation to reported frequency of use while in a moving vehicle or inside buildings. Higher output powers for rural compared with urban use of the SMP were observed principally in Sweden where the study covered very sparsely populated areas. Conclusions: Average power levels are substantially higher than the minimum levels theoretically achievable in GSM networks. Exposure indices could be improved by accounting for average power levels of different telecommunications systems. There appears to be little value in gathering information on circumstances of phone use other than use in very sparsely populated regions.

Collaboration


Dive into the Sarah J. Hepworth's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kenneth Muir

University of Nottingham

View shared research outputs
Top Co-Authors

Avatar

Anthony J. Swerdlow

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Minouk J. Schoemaker

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fay J. Hosking

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Richard S. Houlston

Institute of Cancer Research

View shared research outputs
Researchain Logo
Decentralizing Knowledge